Bronwen Bastone - 05 Jan 2023 Form 4 Insider Report for Enfusion, Inc. (ENFN)

Role
Chief People Officer
Signature
/s/ Matthew Campobasso, as Attorney-in-Fact
Issuer symbol
ENFN
Transactions as of
05 Jan 2023
Transactions value $
$0
Form type
4
Filing time
09 Jan 2023, 16:38:25 UTC
Previous filing
27 Oct 2022
Next filing
27 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENFN Class A Common Stock Award $0 +5,651 +3.59% $0.000000 163,001 05 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENFN Stock Option (Right to Buy) Award $0 +9,343 $0.000000 9,343 05 Jan 2023 Class A Common Stock 9,343 $11.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consist of restricted stock units ("RSUs") awarded pursuant to the Enfusion, Inc. 2021 Stock Option and Incentive Plan (the "Plan"). The RSUs will vest in full as follows: 1,884, 1,884, and 1,883 RSUs will vest on January 5, 2024, January 5, 2025, and January 5, 2026, respectively.
F2 These options were granted under the Plan and shall become exercisable as follows: 3,115, 3,114, and 3,114 on January 5, 2024, January 5, 2025, and January 5, 2026, respectively.

Remarks:

Exhibit 24 - Power of Attorney